Top 10 High Tech Companies To Own For 2014

The California Department of Motor Vehicles said Saturday there is no evidence of a computer breach that could affect credit-card users, but it’s launching an investigation “out of an abundance of caution.”

DMV spokesman Armando Botello said the agency was alerted by law enforcement to a potential security breach within its online credit-card processing systems.

“There is no evidence at this time of a direct breach of the DMV’s computer system,” Botello said in a statement.

But the agency has opened an investigation, and it’s cooperating with state and federal authorities.

As part of the probe, DMV will review its systems and seek information from the outside vendor that processes credit-card transactions and from credit-card companies.

KrebsOnSecurity.com, a website that covers cyber-security problems, was the first to report the possible breach, which it says involved online payments from Aug. 2, 2013, to Jan. 31, 2014.

Top 10 High Tech Companies To Own For 2014: Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Lymphoseek

< /p>

Navidea’s pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body’s immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea’s Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-cent er Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.

AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer’s disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.

RadioImmunoGuided Surgery

As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.

The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Navidea Biopharmaceuticals Inc.(NAVB) said the U.S. Food and Drug Administration has granted a priority review for an expanded use of its Lymphoseek drug for some patients with head and neck cancer. Shares dropped 5.4% to $1.97 premarket.

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Toll Brothers Inc.(TOL) and Navidea Biopharmaceuticals Inc.(NAVB)

  • [By Sean Williams]

    Diagnostics can also play an important role in early and late-stage breast cancer diagnoses. Navidea Biopharmaceuticals (NYSEMKT: NAVB  ) had Lymphoseek, its external lymph-node imaging and intra-operative lymphatic mapping diagnostic device, approved by the Food and Drug Administration earlier this year to help doctors stage cancer. Discovering whether breast cancer has invaded adjacent lymph nodes has never been easier or safer thanks to Lymphoseek, and it can dramatically aid physicians in determining the best course of action for breast cancer patients.

  • [By Keith Speights]

    3. Navidea Biopharmaceuticals (NYSEMKT: NAVB  )
    Some investors were likely befuddled by Navidea’s stock action earlier this year. The company received FDA approval in March for Lymphoseek, its radiopharmaceutical agent used for imaging lymph nodes in patients with breast cancer or melanoma. That was great news, but shares dropped quickly and still haven’t returned to previous levels.

Top 10 High Tech Companies To Own For 2014: Thoratec Corporation(THOR)

Thoratec Corporation engages in the development, manufacture, and marketing of proprietary medical devices used for circulatory support. The company?s primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge, and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising hom e discharge, and post-cardiotomy myocardial recovery. The company also provides CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure. In addition, it offers PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. The company sells its products through direct sales force in the United States, as well as through a network of distributors internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.

Advisors’ Opinion:

  • [By Todd Campbell]

    Competing for heart pump market share
    Abiomed’s products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR  ) and Heartware (NASDAQ: HTWR  ) target the intermediate- and long-term-use market instead.

  • [By Brian Pacampara]

    What: Shares of medical device company Thoratec (NASDAQ: THOR  ) sank 12% today after its quarterly results missed Wall Street expectations.  

Top 10 High Tech Companies To Own For 2014: AZZ Inc (AZZ)

AZZ incorporated, incorporated on March 29, 1956, is an electrical equipment and components manufacturer, serving the global markets of power generation, transmission and distribution, and the general industrial markets, and a provider of hot dip galvanizing services to the North American steel fabrication market. The Company operates in two segments: the Electrical and Industrial Products and Services Segment and the Galvanizing Services Segment. On October 1, 2012, the Company completed the acquisition of substantially all of the assets of Galvcast Manufacturing Inc. On January 2, 2013, the Company acquired G3 Galvanizing Limited (G3), a company with galvanizing operations in Halifax, Nova Scotia. On March 29, 2013, the Company completed its acquisition of Aquilex Specialty Repair and Overhaul LLC. In April 2013, it completed the acquisition of Aquilex Specialty Repair and Overhaul LLC (Aquilex SRO).

Electrical and Industrial Products and Services Segment

The Company’s Electrical and Industrial Products and Services Segment produces engineered specialty electrical products, industrial lighting and tubular products, all of which the Company market and sell both in domestic and international markets. The Company’s electrical products are designed, manufactured and configured to distribute electrical power to and from generators, transformers, switching devices and other electrical configurations and are supplied to the power generation, transmission and distribution markets and the general industrial market. The Company’s industrial products include industrial lighting and tubular products. The Company provides lighting products to the petroleum and food processing industries, and to other industries with lighting challenges. The Company also provides tubular products to the petroleum industry. In addition, the Company’s Electrical and Industrial Products and Services Segment provide electrical and mechanical equipment and services enhancing the safety of nuclear faci! lities.

Galvanizing Services Segment

The Galvanizing Services Segment provides hot dip galvanizing to the steel fabrication industry through facilities located throughout the South, Midwest, East Coast and Southwest of the United States and in the Canadian provinces of Quebec, Ontario and Nova Scotia. Hot dip galvanizing is a metallurgical process in which molten zinc is applied to a customer’s material. As of February 28, 2013, the Company operated thirty-five galvanizing plants, which are located in Alabama, Arkansas, Arizona, Colorado, Indiana, Illinois, Louisiana, Kentucky, Minnesota, Mississippi, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia and West Virginia in the United States and Ontario, Quebec and Nova Scotia in Canada. The Company serves fabricators or manufacturers that provide services to the electrical and telecommunications, bridge and highway, petrochemical and general industrial markets, and numerous original equipment ma nufacturers.

Advisors’ Opinion:

  • [By Eric Volkman]

    AZZ (NYSE: AZZ  ) has released results for its Q4 2013 and trailing 12 months. For the quarter, net sales were just over $140 million, which bettered the $124 million in the same period the previous year. The bottom line also rose, to $13.2 million ($0.52 per diluted share) from Q4 2012’s $11.6 million ($0.46).

  • [By Travis Hoium]

    What: Shares of electrical equipment maker AZZ (NYSE: AZZ  ) dropped as much as 16% today after the company reported earnings.

    So what: Revenue was up 44%, to $183.2 million, but net income fell 9%, to $14.5 million, or $0.57 per share. Analysts expected $197.6 million in revenue and $0.63 in earnings, so the quarter fell well short of expectations. 

Top 10 High Tech Companies To Own For 2014: VALE S.A.(VALE)

Vale S.A. engages in the exploration, production, and sale of basic metals in Brazil. The company also involves in fertilizers, logistics, and steel businesses. The Bulk Material segment consist of iron ore mining and pellet production, as well as its Brazilian Northern and Southern transportation systems, including railroads, ports, and terminals. This segment also includes manganese mining and ferroalloys. The Base Metals segment produces nonferrous minerals, including nickel, copper, and aluminum consisting of aluminum trading activities, alumina refining, aluminum metal smelting, and bauxite mining. The Fertilizers segment provides potash, phosphates, and nitrogen. The Logistic Services segment consists of transportation systems, including ships, ports, and railroads for third party cargos. This segment includes 10,179 kilometers of railroad infrastructure, 8 seaport terminals, 5 general cargo ports, and 2 iron ore export terminals. In addition, it generates energy thr ough hydroelectric power plants. The company was founded in 1942 and is based in Rio de Janeiro, Brazil.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Pick a mining stock, any mining stock, and there’s a very good chance that its future earnings are highly dependent on commodity prices. Rio Tinto (RIO) and Vale (VALE)? That’s iron ore. Freeport McMoRan Copper & Gold (FCX)? That’s copper. Alcoa (AA)? That’s aluminum.

  • [By Ben Levisohn]

    It’s shares have dropped 4.7% to $17.78 at 2:31 p.m. today, joining a selloff that has caused Rio Tinto (RIO) to fall 2.4% to $52.11, BHP Billiton (BHP) to decline 2.8% to $64.82 and Vale (VALE) to drop 3.2% to $12.62.

  • [By Ben Levisohn]

    Shares of Cliffs Natural Resources have fallen 2.7% to $18.59 at today at 3:42 p.m., while Rio Tinto (RIO) has fallen 3.6% to $53.36, BHP Billiton (BHP) has dropped 2.2% to $66.64 and Vale (VALE) has plunged 5% to $13.05.

  • [By Ben Levisohn]

    It can’t just be iron-ore prices that got Cliff’s Natural Resources down. Its shares have dropped 27% this year, while Rio Tinto (RIO) is little change, BHP Billiton (BHP) has ticked up 0.7% and Vale (VALE) has dropped 7.9%.

Top 10 High Tech Companies To Own For 2014: Enzo Biochem Inc. (ENZ)

Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory, a network of approximately 30 patient service centers, a laboratory, and a full-service phlebotomy and in-house logistics department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It provides proteins, antibodies, peptides, small molec ules, labeling probes, dyes, and kits, which offer tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts primarily in the field of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment researches and develops therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company sells its products through its direct sales force; and a network of distributors worldwide. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Advisors’ Opinion:

  • [By CRWE]

    Enzo Biochem Inc. (NYSE:ENZ) is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards.

Top 10 High Tech Companies To Own For 2014: Contango Oil & Gas Co (MCF)

Contango Oil & Gas Company (Contango) is an independent natural gas and oil company. The Company’s core business is to explore, develop, produce and acquire natural gas and oil properties onshore and offshore in the Gulf of Mexico in water-depths of less than 300 feet. Contango Operators, Inc. (COI), its wholly owned subsidiary, acts as operator on its properties.

Offshore Gulf of Mexico Activities

Contango, through its wholly-owned subsidiary, COI and its partially owned affiliate, Republic Exploration LLC (REX), conducts exploration activities in the Gulf of Mexico. COI drills, and operates its wells in the Gulf of Mexico, as well as attends lease sales and acquires leasehold acreage. As of August 24, 2012, the Company’s offshore production was approximately 83.5 million cubic feet equivalent per day, net to Contango, which consists of seven federal and five state of Louisiana wells in the shallow waters of the Gulf of Mexico. These 12 operate d wells produce through the four platforms: Eugene Island 24 Platform, Eugene Island 11 Platform, Ship Shoal 263 Platform, Vermilion 170 Platform and Other Activities.

This third-party owned and operated production platform at Eugene Island 24 was designed with a capacity of 100 million cubic feet per day and 3,000 barrels of oil per day. This platform services production from the Company’s Dutch #1, #2 and #3 federal wells. From this platform, the gas flows through an American Midstream pipeline into a third-party owned and operated on-shore processing facility at Burns Point, Louisiana, and the condensate flows through an ExxonMobil pipeline to on-shore markets and multiple refineries. As of August 24, 2012, it was producing approximately 22.5 million cubic feet equivalent per day, net to Contango, from this platform. The Company finished laying six inches auxiliary flowlines from the Dutch #1, #2, and #3 wells to its Eugene Island 11 Platform and is in the process of redirecting production from the Eugene Island 24! Platform to the Eugene Island 11 Platform.

The Company’s Company-owned and operated platform at Eugene Island 11 was designed with a capacity of 500 million cubic feet equivalent per day and 6,000 barrels of oil per day. These platforms service production from the Company’s five Mary Rose wells, which are all located in state of Louisiana waters, as well as its Dutch #4 and Dutch #5 wells, which are both located in federal waters. From these platforms, it can flow its gas to an American Midstream pipeline through its eight inches pipeline and from there to a third-party owned and operated on-shore processing facility at Burns Point, Louisiana. It can flow its condensate through an ExxonMobil pipeline to on-shore markets and multiple refineries.

The Company’s gas and condensate can flow to its Eugene Island 63 auxiliary platform through its 20 inches pipeline, which has been designed with a capacity of 330 million cubic feet equivalent per da y and 6,000 barrels of oil per day, and from there to third-party owned and operated on-shore processing facilities near Patterson, Louisiana, through an ANR pipeline. As of August 24, 2012, it was producing approximately 44.6 million cubic feet equivalent per day, net to Contango, from this platform.

The Company’s owned and operated platform at Ship Shoal 263 was designed with a capacity of 40 million cubic feet equivalent per day and 5,000 barrels of oil per day. This platform services natural gas and condensate production from our Nautilus well, which flows through the Transcontinental Gas Pipeline to onshore processing plants. As of August 24, 2012, it was producing approximately 3.0 million cubic feet equivalent per day, net to Contango, from this platform. As of June 30, 2012, the Company owed a 100% working interest and 80% net revenue interest in this well and platform.

The Company’s owned and operated platform at Vermilion 170 was desig ned with a capacity of 60 million cubic feet equivalent per ! day and 2! ,000 barrels of oil per day. This platform services natural gas and condensate production from its Swimmy well, which flows through the Sea Robin Pipeline to onshore processing plants. As of August 24, 2012, it was producing approximately 13.4 million cubic feet equivalent per day, net to Contango, from this platform.

On July 10, 2012, the Company spud its South Timbalier 75 prospect (Fang) with the Spartan 303 rig. It has a 100% working interest in this wildcat exploration prospect. On July 3, 2012, the Company spud its Ship Shoal 134 prospect (Eagle) with the Hercules 205 rig. The Company purchased the deep mineral rights on Ship Shoal 134 from an independent third-party. It has a 100% working interest in this wildcat exploration prospect. On December 21, 2011, the Company purchased an additional 3.66% working interest (2.67% net revenue interest) in Mary Rose #5 (previously Eloise North). The Company has a 47.05% working interest (38.1% net revenue int erest) in Dutch #5.

Offshore Properties

During the fiscal year ended June 30, 2012 (fiscal 2012), State Lease 19396 expired and was returned to the state of Louisiana. As of August 24, 2012, the interests owned by Contango through its affiliated entities in the Gulf of Mexico, which were capable of producing natural gas or oil included Eugene Island 10 #D-1, Eugene Island 10 #E-1, Eugene Island 10 #F-1, Eugene Island 10 #G-1, Eugene Island 10 #I-1, S-L 18640 #1, S-L 19266 #1, S-L 19266 #2, S-L 18860 #1, S-L 19266 #3 and S-L 19261, Ship Shoal 263, Vermilion 170 and West Delta 36. As of August 24, 2012, interests owned by Contango through its related entities in leases in the Gulf of Mexico included Eugene Island 11, East Breaks 369, South Timbalier 97, Ship Shoal 121, Ship Shoal 122, Brazos Area 543, Ship Shoal 134 and South Timbalier 75.

Onshore Exploration and Properties

As of August 24, 2012, the Company had invested in A lta Energy Canada Partnership (Alta Energy) to purchase over! 60,000 a! cres in the Kaybob Duvernay. Contango has a 2% interest in Alta Energy and a 5% interest in the Kaybob Duvernay project. On April 9, 2012, the Company announced that through its wholly owned subsidiary, Contaro Company, it had entered into a Limited Liability Company Agreement (the LLC Agreement) to form Exaro Energy III LLC (Exaro). The Company owns approximately a 45% interest in Exaro. Exaro has entered into an Earning and Development Agreement (the EDA Agreement) with Encana Oil & Gas (USA) Inc. (Encana) to provide funding to continue the development drilling program in a defined area of Encana’s Jonah field asset located in Sublette County, Wyoming.

As of June 30, 2012, the Exaro-Encana venture had three rigs drilling, has completed five wells and achieved first production. As of August 24, 2012, the Company had invested to lease approximately 25,000 acres in the Tuscaloosa Marine Shale (TMS), a shale play in central Louisiana and Mississippi.

Advisors’ Opinion:

  • [By John Udovich]

    Yesterday, small cap Energy XXI (Bermuda) Limited (NASDAQ: EXXI) announced a deal to acquire EPL Oil & Gas Inc (NYSE: EPL) to create the largest publicly held independent oil producer on the Gulf of Mexico shelf, meaning it might be a good idea to look at other small cap Gulf oil stocks like W&T Offshore, Inc (NYSE: WTI), Stone Energy Corporation (NYSE: SGY) and Contango Oil & Gas Company (NYSEMKT: MCF). Energy XXI’s CEO John Schiller has talked about the details of the acquisition with Jim Cramer on CNBC’s “Mad Money” and he noted that  EPL Oil & Gas offers areas of expertise that EXXI currently lacks. However, investors who missed out on yesterday’s 29% surge for EPL Oil & Gas may want to check out these other small cap Gulf Oil stocks:

  • [By Peter Krauth]

    But the dynamic is suddenly changing. This is a pricing game—a global one. You see, while North Americans currently enjoy natural gas at close to $3.40 per million cubic feet (Mcf), Europeans are paying three times as much, between $10 and $11 per Mcf.

Top 10 High Tech Companies To Own For 2014: Harte-Hanks Inc. (HHS)

Harte-Hanks, Inc., a direct and targeted marketing company, provides multichannel direct and digital marketing services, and shopper advertising opportunities to a range of local, regional, national, and international consumer and business-to-business marketers in the United States and other countries. It offers integrated, multichannel, and data-driven solutions for various brands to retail, high-tech/telecom, financial services, and pharmaceutical/healthcare markets. The company provides agency and digital services, including Website development and design, digital strategy, social media marketing and monitoring, email marketing, and ecommerce and interactive relationship management services; database marketing solutions that enable organizations to build and manage customer communication strategies; and Trillium Software System, a global locator geocoding product, as well as associated data governance services. It also offers direct mail and fulfillment, and business-to -business lead generation services, as well as operates teleservice workstations that provide advanced contact center solutions. The company has a strategic partnership with GX Software. Harte-Hanks, Inc. was founded in 1970 and is headquartered in San Antonio, Texas.

Advisors’ Opinion:

  • [By Eric Volkman]

    There will soon be a new moniker on the CEO nameplate at Harte-Hanks (NYSE: HHS  ) . The company has picked Robert Philpott to replace outgoing Chief Executive Larry Franklin, who will retire on June 30. Philpott, who was selected following a global search led by a board of directors committee, will also assume Franklin’s role as president of the company.

  • [By Luke Jacobi]

    Harte-Hanks (NYSE: HHS) shot up 6.76 percent to $8.53 after BMO Capital upgraded the stock from Market Perform to Outperform.

    Facebook (NASDAQ: FB) gained 3.78 percent to $51.04. Facebook’s Instagram reported that it will introduce advertisements in the coming months. Sterne Agee raised the price target on the stock from $50.00 to $58.00.

Top 10 High Tech Companies To Own For 2014: Pennsylvania Real Estate Investment Trust (PEI)

Pennsylvania Real Estate Investment Trust (PREIT), incorporated on September 29, 1997, is a fully integrated, self-managed and self-administered real estate investment trust (REIT). The Company has a primary investment focus on retail shopping malls located in the eastern half of the United States, primarily in the Mid-Atlantic region. As of December 31, 2012, the Company owned interests in 46 retail properties, of which 42 were operating properties, three were development properties and one was classified as held for sale. The 42 operating properties, which are classified in continuing operations, include 36 enclosed malls and six strip and power centers, have a total of 30.7 million square feet and operate in 12 states. The Company and partnerships in which the Company owns an interest owned 23.9 million square feet at these properties (excluding space owned by anchors). The development portion of the Company’s portfolio contains three properties in two states, with two classified as mixed use (a combination of retail and other uses) and one classified as other. In January 2013, the Company sold its interests in Paxton Towne Centre in Harrisburg, Pennsylvania and Phillipsburg Mall in Phillipsburg, New Jersey. In February 2013, the Company sold Orlando Fashion Square in Orlando, Florida. In November 2013, the Company sold Chambersburg Mall in Chambersburg, PA.

As of December 31, 2012, the Company had four properties, which were classified as held for sale, two of which were malls and two of which were power centers. The Company is engaged in the ownership, management, leasing, acquisition, redevelopment and development of enclosed malls. The Company’s malls include national or regional department stores, large format retailers or other anchors and a diverse mix of national, regional and local in-line stores offering apparel (women’s, family, teen, children’s, men’s), shoes, eyewear, cards and gifts, jewelry, sporting goods, hom e furnishings, drug stores, electronics and books/music/movi! es, among other things. Its malls have restaurants and/or food courts, and some of the malls have multi-screen movie theaters and other entertainment options, either as part of the mall or on outparcels around the perimeter of the mall property. In addition, its malls have outparcels containing restaurants, banks or other stores. It derives its revenue from rent received under leases with tenants for space at retail properties in its real estate portfolio.

Advisors’ Opinion:

  • [By Marc Bastow]

    Retail shopping mall real estate investment trust Pennsylvania REIT (PEI) raised its quarterly dividend 11% to 20 cents per share, payable on Dec. 16 to shareholders of record as of Dec. 2.
    PEI Dividend Yield: 4.74%

  • [By Rich Duprey]

    Pennsylvania Real Estate Investment Trust  (NYSE: PEI  )  reported first-quarter results yesterday that were below consensus expectations on the top line but came in ahead on the bottom line, causing the company to raise guidance for the full year.

Top 10 High Tech Companies To Own For 2014: Strategic Diagnostics Inc.(SDIX)

Strategic Diagnostics Inc., a biotechnology company, develops, commercializes, and markets proprietary products, services, and solutions for the pharmaceutical, biotechnology, diagnostics, food safety, and environmental markets. Its life science portfolio includes products and custom services that supply critical reagents used across the life science research and development markets. These products and services include custom antibodies, in-vitro diagnostic-grade antibodies, proprietary critical reagent products, associated bio-processing services, and custom assay design and development services that are sold to pharmaceutical, biotechnology, and diagnostic companies, as well as to biomedical research centers. The company also provides Kit products, including immunoassays, which represent advanced technology for the detection of food pathogens and soil contaminants. Its detection technologies allow industrial customers to identify the presence of adulterants, such as chem ical toxins, biological pathogens, and other contaminants, which can compromise human or environmental safety, and/or impact efficiencies of production processes. These products are used in various applications, including food and beverage manufacturing, environmental management, and agriculture and agro-science. The company markets and sells its products in the life sciences, and food safety product categories through a direct sales force, Internet, and a network of distributors, as well as through its corporate partners in the United States, Canada, Mexico, Latin America, Europe, and Asia. Strategic Diagnostics Inc. was founded in 1987 and is headquartered in Newark, Delaware.

Advisors’ Opinion:

  • [By CRWE]

    SDIX (Nasdaq:SDIX) – a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic, and food safety applications, expects to release its second quarter 2012 results at approximately 4 p.m. ET on Wednesday, August 8, 2012.

Top 10 High Tech Companies To Own For 2014: GTx Inc.(GTXI)

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women primarily through wholesale drug distributors in the United States. It is developing selective androgen receptor modulators (SARMs), including Ostarine (GTx-024), which has completed Phase II clinical trial for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer; and CapesarisTM (GTx-758), a selective estrogen receptor alpha agonist that has completed Phase IIa clinical trial for the first line treatment of advanced prostate cancer. In addition, the company is developing estrogen receptor beta agonists and other novel compounds that are in preclinical development stage for the treatment of metabo lic diseases, ophthalmic diseases, cancer, psoriasis, and/or pain. The company was founded in 1997 and is headquartered Memphis, Tennessee.

Advisors’ Opinion:

  • [By James E. Brumley]

    If you were lucky enough to step into Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) when your truly suggested it was a budding buy back on December 23rd, then congratulations – you’re now up a little more than 60% (assuming you bought into RNN after the break above a key resistance line on the 27th). Now get out. Instead, use your profits from the Rexahn to take on a stake in GTx, Inc. (NASDAQ:GTXI). No, GTXI may not look like much at first, but when you take a step back and look at a chart of GTx, Inc. through a longer-term lens, the upside potential becomes clear.

  • [By John Udovich]

    Cancer has been one of the hotter segments of the sizzling biotech sector this year with small cap cancer stocks Genetics Inc (NASDAQ: CGIX), GTx, Inc (NASDAQ: GTXI) and MetaStat Inc (OTCMKTS: MTST) being among those involved in cancer research or treatment producing noteworthy news for investors to digest. Just consider the following:

  • [By Keith Speights]

    War of words
    In the stock market, the old saying that “sticks and stones may break my bones, but words can never hurt me” doesn’t hold water. GTx (NASDAQ: GTXI  ) investors experienced that reality firsthand this week, with shares dropping 15% from an online article published on Wednesday.

  • [By Paul Ausick]

    GTX Inc. (NASDAQ: GTXI) is down 66.9% at $1.38 after posting a new 52-week low of $1.31 earlier today. The biopharmaceutical maker’s shares collapsed on news of a failed trial for its muscle drug.